---
layout: summary
title: Does remdesivir, an antiviral medication, speed up how quickly hospitalized COVID-19 patients get better?
description: In this study, researchers randomly administered either remdesivir or placebo to 237 patients. They found that remdesivir was safe to take but not associated with treatment benefits.
research_title: Remdesivir in adults with severe COVID-19 - a randomised, double-blind, placebo-controlled, multicentre trial
research_link: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext
research_pdf: https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931022-9
doi: 10.1016/S0140-6736(20)31022-9
version: 1
preprint: false
preview: false
include_js: true
published_on: 2020-05-30
---

<h2>What did the study do?</h2>

<ul class="timeline timeline-split">
  <li class="timeline-item">
    <div class="timeline-info">
      <span>Sampling</span>
    </div>
    <div class="timeline-marker">
      <svg height='2em' width='2em' style="margin-left: -0.6em; margin-top: -0.2em;" fill="#000000" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 100 100" enable-background="new 0 0 100 100" xml:space="preserve"><path d="M35.635,36.152V17.668h27.47v18.484h18.48v27.469h-18.48v18.486h-27.47V63.621H17.151V36.152H35.635z M20.19,39.193v21.391  h18.484v18.482h21.39V60.584h18.484V39.193H60.064V20.709h-21.39v18.484H20.19z"></path></svg>
    </div>
    <div class="timeline-content">
      <h3 class="timeline-title">Enrolled patients with COVID-19 from 10 hospitals</h3>
      {% include expand_details.html positive_count=1 warning_count=1 %}
      <div class="collapsible">
        <h4>Our Take</h4>
        <h5>{% include pos.html %} Realistic study population</h5>
        <p>
          The study population was very applicable to the real world. It consisted of patients who were admitted to the hospital with SARS-CoV-2 pneumonia (confirmed by PCR testing and chest imaging) and who required supplemental oxygen or other respiratory support. The study design required enrollment, and hence, hospital admission, to occur within 12 days of symptom onset. This is probably applicable for most, if not all, COVID-19 patients who come to the hospital in the real world.
        </p>
        <h5>{% include neg.html %} Patients used other medications</h5>
        <p>
          Patients enrolled in this study were allowed to receive other medications. Although this is not totally avoidable for ethical reasons, these medications included the antiviral medication lopinavir-ritonavir, the antiviral and immune modulating medication interferon alfa-2b, and anti-inflammatory and immunosuppressive steroids. 29% of patients in the remdesivir group received interferon alfa-2b compared to 38% in the placebo group, a potentially noteworthy difference. On the other hand, similar numbers of patients received lopinavir-ritonavir (28% and 29%) and steroids (65% and 68%) in the two groups. Unfortunately, the investigators did not report the doses of these medications so that we could better compare whether the patients were treated similarly in the two groups.
        </p>
        {% include hide_details.html %}
      </div>
    </div>
  </li>
  <li class="timeline-item">
    <div class="timeline-info">
      <span>Treatment</span>
    </div>
    <div class="timeline-marker">
      <svg height='2em' width='2em' style="margin-left: -0.6em; margin-top: -0.2em;" fill="#000000" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512;" xml:space="preserve"><path d="M387.9111023,124.0889053c-14.2851257-14.2861938-33.3503418-22.15271-53.6844482-22.15271  s-39.399292,7.8665161-53.6844482,22.15271L124.0889053,280.5422058  c-14.2861938,14.2851562-22.15271,33.3503418-22.15271,53.6844482s7.8665161,39.3993225,22.15271,53.6844482  c14.2851334,14.2861938,33.3503342,22.15271,53.6844406,22.15271s39.3993073-7.8665161,53.684433-22.15271l156.4533234-156.4533234  c14.2861938-14.2851257,22.15271-33.3503418,22.15271-53.684433S402.1972961,138.3740387,387.9111023,124.0889053z   M223.0224915,379.4757996c-24.9521179,24.9500122-65.5461731,24.9500122-90.498291,0  c-24.9500046-24.9510498-24.9500046-65.5472412,0-90.498291l76.6929626-76.6929626l90.498291,90.498291L223.0224915,379.4757996z   M379.4757996,223.0224915l-71.3250427,71.3250427l-90.4983063-90.498291l71.325058-71.3250427  c12.4760742-12.4750061,28.8626099-18.7125015,45.2491455-18.7125015s32.7731018,6.2374954,45.2491455,18.7125015  C404.4258118,157.4752502,404.4258118,198.0714264,379.4757996,223.0224915z"></path></svg>
    </div>
    <div class="timeline-content">
      <h3 class="timeline-title">Randomized patients to receive either remdesivir or placebo</h3>
      <div style="height: 300px">
        <canvas id="treatmentChart"></canvas>
      </div>
      {% include expand_details.html positive_count=1 %}
      <div class="collapsible">
        <h4>Our Take</h4>
        <h5>
          {% include pos.html %} Randomized double-blinded placebo-controlled study design
        </h5>
        <p>
          This study was a prospective randomized double-blinded placebo-controlled trial. This is widely considered to provide the highest quality of clinical evidence by preventing confounding (hidden differences that impact outcomes) between the treatment and control groups. The authors assigned patients to remdesivir or placebo in a 2:1 ratio, which is an accepted strategy to control the number of patients in each treatment group. The authors stratified the randomization according to whether or not patients required respiratory support, which partially helped to ensure that the patients in one group of the trial were not far sicker than the patients in the other group at the beginning of the trial.
        </p>
        {% include hide_details.html %}
      </div>
    </div>
  </li>
  <li class="timeline-item">
    <div class="timeline-info">
      <span>Analysis</span>
    </div>
    <div class="timeline-marker">
      <svg height='2em' width='2em' style="margin-left: -0.6em; margin-top: -0.2em;" fill="#000000" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 100 100" enable-background="new 0 0 100 100" xml:space="preserve"><g><path fill="none" d="M45.633,8.08c-8.238,0.345-16.013,3.496-22.181,8.991l22.181,22.896V8.08z"></path><path fill="none" d="M9.835,51.544c0,6.928,1.973,13.588,5.721,19.367l27.633-19.584L19.626,27.002   C13.3,33.662,9.835,42.317,9.835,51.544z"></path><path fill="none" d="M89.84,50.735c-0.077-0.581-0.168-1.158-0.273-1.734c-0.229-1.257-0.52-2.487-0.861-3.648   c-0.15-0.517-0.312-1.025-0.483-1.526c-0.371-1.093-0.801-2.179-1.277-3.236c-0.208-0.465-0.424-0.913-0.648-1.362   c-0.49-0.977-1.036-1.95-1.622-2.895c-0.253-0.405-0.511-0.813-0.785-1.214c-0.67-0.985-1.397-1.95-2.159-2.863   c-0.304-0.364-0.615-0.721-0.932-1.077c-0.7-0.773-1.455-1.538-2.243-2.271c-0.346-0.324-0.701-0.641-1.059-0.949   c-0.811-0.701-1.66-1.37-2.525-1.99c-0.391-0.284-0.782-0.557-1.181-0.821c-0.945-0.629-1.892-1.197-2.822-1.694   c-0.439-0.24-0.883-0.465-1.33-0.685c-1.139-0.557-2.326-1.057-3.523-1.49c-0.494-0.18-0.992-0.352-1.494-0.508   c-1.17-0.368-2.378-0.677-3.593-0.929c-0.561-0.112-1.129-0.216-1.701-0.304c-1.327-0.204-2.713-0.337-4.121-0.388   c-0.227-0.008-0.453-0.02-0.681-0.024v36.027c0,0.493-0.239,0.957-0.642,1.241L24.503,77.219c0.502,0.673,1.05,1.354,1.669,2.07   c0.306,0.353,0.619,0.709,0.942,1.053c0.704,0.757,1.47,1.51,2.283,2.239c0.354,0.316,0.715,0.629,1.078,0.933   c1.007,0.833,1.942,1.542,2.854,2.163c0.328,0.22,0.665,0.429,1.004,0.637l0.224,0.14c0.947,0.589,1.922,1.133,2.896,1.626   c0.441,0.22,0.892,0.441,1.352,0.649c0.991,0.449,2.053,0.861,3.248,1.27c0.501,0.168,1.007,0.337,1.519,0.484   c1.274,0.373,2.465,0.661,3.645,0.877c0.573,0.104,1.152,0.188,1.735,0.264c1.581,0.212,3.16,0.32,4.694,0.324   c0.023,0,0.081,0.004,0.104,0.004c0.656,0.008,1.305-0.02,1.951-0.052c1.723-0.092,3.461-0.312,5.166-0.649   c0.853-0.172,1.717-0.38,2.641-0.641c2.649-0.733,5.197-1.762,7.574-3.056c2.384-1.298,4.643-2.879,6.714-4.71   c1.162-1.025,2.257-2.122,3.259-3.26c1.834-2.078,3.42-4.337,4.713-6.716c1.291-2.371,2.319-4.918,3.059-7.569   c0.259-0.937,0.467-1.806,0.636-2.647c0.337-1.698,0.557-3.436,0.651-5.166c0.033-0.645,0.052-1.297,0.052-1.954l-0.001-0.104   C90.159,53.915,90.05,52.333,89.84,50.735z"></path><path d="M46.063,44.788c0.293,0.304,0.69,0.464,1.094,0.464c0.192,0,0.387-0.036,0.572-0.112c0.575-0.232,0.951-0.789,0.951-1.41   V6.522C48.68,5.681,47.998,5,47.157,5c-10.104,0-19.672,3.877-26.94,10.917c-0.29,0.284-0.456,0.665-0.463,1.069   c-0.006,0.404,0.148,0.797,0.43,1.085L46.063,44.788z M45.633,8.08v31.886L23.453,17.071C29.62,11.576,37.395,8.424,45.633,8.08z"></path><path d="M47.035,51.684c0.041-0.44-0.112-0.881-0.422-1.201L20.731,23.767c-0.281-0.288-0.665-0.456-1.069-0.461   c-0.404,0.004-0.794,0.148-1.083,0.429c-7.603,7.365-11.79,17.241-11.79,27.809c0,8.074,2.47,15.815,7.139,22.387   c0.296,0.42,0.767,0.645,1.244,0.645c0.303,0,0.612-0.092,0.879-0.28l30.348-21.51C46.763,52.529,46.995,52.128,47.035,51.684z    M15.556,70.911c-3.748-5.779-5.721-12.439-5.721-19.367c0-9.227,3.465-17.881,9.791-24.542l23.563,24.325L15.556,70.911z"></path><path d="M93.21,55.421c-0.006-1.646-0.124-3.356-0.35-5.082c-0.083-0.633-0.183-1.262-0.294-1.882   c-0.25-1.366-0.566-2.699-0.934-3.957c-0.161-0.556-0.337-1.109-0.524-1.654c-0.402-1.185-0.869-2.367-1.384-3.504   c-0.223-0.501-0.458-0.993-0.702-1.478c-0.533-1.061-1.123-2.115-1.759-3.14c-0.278-0.449-0.56-0.889-0.853-1.318   c-0.726-1.069-1.512-2.111-2.338-3.1c-0.328-0.392-0.663-0.781-1.009-1.165c-0.759-0.841-1.577-1.67-2.43-2.463   c-0.374-0.348-0.756-0.693-1.144-1.025c-0.877-0.757-1.798-1.486-2.731-2.155c-0.425-0.308-0.853-0.609-1.284-0.889   c-1.017-0.677-2.049-1.298-3.059-1.838c-0.473-0.256-0.953-0.501-1.437-0.737c-1.238-0.605-2.524-1.15-3.822-1.618   c-0.537-0.196-1.077-0.384-1.624-0.553c-1.264-0.397-2.573-0.737-3.894-1.005c-0.608-0.124-1.221-0.232-1.842-0.332   c-1.443-0.22-2.948-0.365-4.468-0.421c-0.526-0.02-1.053-0.04-1.583-0.04c-1.249,0-2.263,1.013-2.263,2.263v36.035L22.092,75.192   c-0.49,0.345-0.827,0.877-0.928,1.478c-0.097,0.593,0.039,1.185,0.388,1.682l0.147,0.196c0.639,0.885,1.348,1.778,2.169,2.731   c0.335,0.389,0.674,0.773,1.021,1.145c0.761,0.817,1.592,1.63,2.472,2.423c0.382,0.34,0.771,0.677,1.166,1.005   c1.087,0.905,2.099,1.67,3.095,2.347c0.365,0.244,0.738,0.477,1.11,0.705l0.219,0.136c1.023,0.637,2.075,1.225,3.138,1.762   c0.486,0.244,0.973,0.48,1.464,0.701c1.078,0.488,2.229,0.937,3.521,1.378c0.545,0.188,1.093,0.365,1.644,0.525   c1.372,0.4,2.661,0.713,3.95,0.949c0.626,0.116,1.253,0.204,1.881,0.288c1.709,0.228,3.421,0.348,5.048,0.352   c0.026,0,0.121,0.004,0.147,0.004c0.713,0,1.42-0.02,2.12-0.06c1.867-0.096,3.751-0.332,5.6-0.705   c0.929-0.184,1.865-0.408,2.863-0.689c2.869-0.797,5.632-1.91,8.212-3.316c2.585-1.406,5.033-3.124,7.275-5.102   c1.257-1.105,2.445-2.295,3.527-3.528c1.984-2.247,3.702-4.694,5.105-7.277c1.399-2.571,2.514-5.331,3.316-8.21   c0.28-1.013,0.507-1.947,0.689-2.864c0.366-1.842,0.603-3.724,0.706-5.603c0.035-0.701,0.056-1.406,0.056-2.114L93.21,55.421z    M90.113,57.487c-0.094,1.73-0.313,3.468-0.651,5.166c-0.168,0.841-0.376,1.71-0.636,2.647c-0.74,2.651-1.768,5.198-3.059,7.569   c-1.293,2.379-2.879,4.638-4.713,6.716c-1.001,1.137-2.096,2.235-3.259,3.26c-2.072,1.83-4.33,3.412-6.714,4.71   c-2.377,1.293-4.925,2.323-7.574,3.056c-0.924,0.26-1.788,0.469-2.641,0.641c-1.705,0.337-3.443,0.557-5.166,0.649   c-0.647,0.032-1.296,0.06-1.951,0.052c-0.023,0-0.081-0.004-0.104-0.004c-1.534-0.004-3.113-0.112-4.694-0.324   c-0.583-0.076-1.162-0.16-1.735-0.264c-1.179-0.216-2.371-0.505-3.645-0.877c-0.512-0.148-1.018-0.316-1.519-0.484   c-1.195-0.408-2.257-0.821-3.248-1.27c-0.46-0.208-0.911-0.428-1.352-0.649c-0.973-0.492-1.948-1.037-2.896-1.626l-0.224-0.14   c-0.34-0.208-0.677-0.417-1.004-0.637c-0.912-0.621-1.847-1.33-2.854-2.163c-0.363-0.304-0.724-0.617-1.078-0.933   c-0.813-0.729-1.579-1.482-2.283-2.239c-0.323-0.345-0.636-0.701-0.942-1.053c-0.619-0.717-1.167-1.398-1.669-2.07l29.382-20.825   c0.403-0.284,0.642-0.749,0.642-1.241V19.125c0.227,0.004,0.454,0.016,0.681,0.024c1.408,0.052,2.794,0.184,4.121,0.388   c0.572,0.088,1.14,0.192,1.701,0.304c1.215,0.252,2.423,0.561,3.593,0.929c0.502,0.156,1,0.328,1.494,0.508   c1.197,0.433,2.384,0.933,3.523,1.49c0.447,0.22,0.891,0.445,1.33,0.685c0.93,0.497,1.877,1.065,2.822,1.694   c0.399,0.264,0.79,0.537,1.181,0.821c0.865,0.621,1.714,1.29,2.525,1.99c0.358,0.308,0.713,0.625,1.059,0.949   c0.788,0.733,1.543,1.498,2.243,2.271c0.317,0.357,0.628,0.713,0.932,1.077c0.762,0.913,1.489,1.878,2.159,2.863   c0.273,0.4,0.532,0.809,0.785,1.214c0.586,0.945,1.131,1.918,1.622,2.895c0.224,0.449,0.44,0.897,0.648,1.362   c0.476,1.057,0.906,2.143,1.277,3.236c0.171,0.501,0.332,1.009,0.483,1.526c0.341,1.161,0.632,2.391,0.861,3.648   c0.105,0.577,0.196,1.153,0.273,1.734c0.209,1.598,0.319,3.18,0.323,4.694l0.001,0.104C90.165,56.189,90.146,56.842,90.113,57.487z   "></path></g></svg>
    </div>
    <div class="timeline-content">
      <h3 class="timeline-title">Compared improvement in remdesivir group with the placebo group</h3>
      {% include expand_details.html positive_count=3 warning_count=1 %}
      <div class="collapsible">
        <h4>Our Take</h4>
        <h5>
          {% include neg.html %} Unusual primary objectve
        </h5>
        <p>
          The study investigators defined a 6-point clinical severity scale, with 6 representing death, 5 representing ECMO or mechanical ventilation, 4 representing non-invasive positive pressure ventilation or high-flow oxygen therapy, 3 representing oxygen therapy, 2 representing hospital admission and 1 representing feeling well enough to go home from the hospital. They looked at how quickly each patient achieved a 2-point reduction on this scale. This clinical scale is reasonable, but it had not been used prior to this study. It is more widely accepted to analyze endpoints such as mortality that can be easily compared across studies.
        </p>
        <h5>
          {% include pos.html %} Analyzed mortality as a secondary objective
        </h5>
        <p>
          The study investigators also compared the mortality between the two arms of the trial at multiple time points. This was useful because it presented the study results in terms of a widely accepted metric.
        </p>
        <h5>
          {% include pos.html %} Use of standardized statistical methods
        </h5>
        <p>
          Although the 6-point clinical scale devised by the investigators was unusual, their use of a statistical technique, called the <a href="https://en.wikipedia.org/wiki/Proportional_hazards_model">Cox proportional hazards model</a>, to compare the two study groups is widely accepted in clinical literature.
        </p>
        <p>
          The study investigators performed intention-to-treat analysis, a form of data analysis that analyzes the patients in their assigned group even if they have to drop out of the study for some reason. This is a widely accepted method to avoid obtaining misleading results.
        </p>
        <h5>
          {% include pos.html %} 28-day follow-up
        </h5>
        <p>
          The patients in the study were followed for 28 days, which was long enough to determine what happened to most, but not all, of the patients. At the end of the study, the clinical outcome had still not been determined for 16% of remdesivir patients and 20% of placebo patients.
        </p>
        {% include hide_details.html %}
      </div>
    </div>
  </li>
  <li class="timeline-item">
    <div class="timeline-info">
      <span>Findings</span>
    </div>
    <div class="timeline-marker">
      <svg height='2em' width='2em' style="margin-left: -0.6em; margin-top: -0.2em;" fill="#000000" xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 100 100" x="0px" y="0px"><g data-name="Group"><path data-name="Compound Path" d="M73.6,14.8H58.1a8.5,8.5,0,0,0-16.2,0H26.4a9.1,9.1,0,0,0-9,9V82.1a9,9,0,0,0,9,9H73.6a9,9,0,0,0,9-9V23.8A9.1,9.1,0,0,0,73.6,14.8Zm-31,2a1,1,0,0,0,1-.8,6.6,6.6,0,0,1,12.8,0,1,1,0,0,0,1,.8H62L65.9,28c.1.4.1.7-.1.9a1.1,1.1,0,0,1-.9.5h-30a1.2,1.2,0,0,1-.8-.4,1,1,0,0,1-.2-.9L37,16.8Zm38,65.3a7,7,0,0,1-7,7H26.4a7,7,0,0,1-7-7V23.8a7.1,7.1,0,0,1,7-7h8.5L32,27.6a2.8,2.8,0,0,0,.5,2.6,3.1,3.1,0,0,0,2.4,1.2h30a3.1,3.1,0,0,0,2.5-1.3,2.9,2.9,0,0,0,.4-2.7L64.2,16.8h9.4a7.1,7.1,0,0,1,7,7Z"></path><path data-name="Path" d="M30.1,45.7H49.9a1,1,0,0,0,1-1,.9.9,0,0,0-1-1H30.1a.9.9,0,0,0-1,1A1,1,0,0,0,30.1,45.7Z"></path><path data-name="Path" d="M69.9,56.7H30.1a.9.9,0,0,0-1,1,1,1,0,0,0,1,1H69.9a1,1,0,0,0,1-1A.9.9,0,0,0,69.9,56.7Z"></path><path data-name="Path" d="M69.9,69.7H30.1a.9.9,0,0,0-1,1,1,1,0,0,0,1,1H69.9a1,1,0,0,0,1-1A.9.9,0,0,0,69.9,69.7Z"></path></g></svg>
    </div>
    <div class="timeline-content">
      <h3 class="timeline-title">No significant difference between remdesivir and placebo groups</h3>
      <table width="100%" style="margin: 10px 0 20px 0">
        <tr>
          <th width="40%"></th>
          <th width="30%">Remdesivir</th>
          <th width="30%">Placebo</th>
        </tr>
        <tr>
          <td>Mortality</td>
          <td>14%</td>
          <td>13%</td>
        </tr>
        <tr>
          <td>Days to Recover</td>
          <td>21</td>
          <td>23</td>
        </tr>
        <tr>
          <td>Adverse Events</td>
          <td>66%</td>
          <td>64%</td>
        </tr>
      </table>
      {% include expand_details.html positive_count=2 %}
      <div class="collapsible">
        <p>
          After 28 days, 14% of remdesivir patients and 13% of placebo patients had died. This difference was not statistically significant. Of the remdesivir patients who survived, it took them an average of 21 days to clinically improve on the 6-point scale devised by the investigators, compared to 23 days for the placebo patients. This difference was not statistically significant. The rate of adverse events was similar between the remdesivir (66%) and placebo (64%) groups, suggesting that the medication was relatively safe.
        </p>
        <h4>Our Take</h4>
        <h5>{% include pos.html %} Meaningful results even though trial was halted early</h5>
        <p>
          In the Methods section of the paper, the investigators described how they initially intended to enroll 453 patients (rather than the 236 who were actually enrolled), but the trial had to be halted early because the initial outbreak was controlled in Wuhan, Hubei, China. However, the number of patients enrolled in the trial was probably sufficient to tell us that even if remdesivir helps patients with SARS-CoV-2 pneumonia, it is unlikely to be the magic bullet many had hoped.
        </p>
        <h5>{% include pos.html %} Reasonable conclusion</h5>
        <p>
          The study investigators arrived at a suitable conclusion based upon the data.
        </p>
        {% include hide_details.html %}
      </div>
    </div>
  </li>
</ul>

<h2>How was it reported?</h2>

<ul class="timeline timeline-split">
  {% include media_review.html
    link="https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/"
    title="New data on Gileadâ€™s remdesivir, released by accident, show no benefit for coronavirus patients. Company still sees reason for hope"
    score=8 content="review1"
  %}

  {% include media_review.html
    link="https://www.barrons.com/news/antiviral-remdesivir-showed-no-significant-benefit-in-virus-patients-01588174805"
    title="Antiviral Remdesivir Showed 'No Significant Benefit' In Virus Patients"
    score=7 content="review2"
  %}
</ul>
